Evidence map›Paper›PMID 37891810›Full record

ReviewBrain sciences2023

Current Challenges in the Diagnosis of Progressive Neurocognitive Disorders: A Critical Review of the Literature and Recommendations for Primary and Secondary Care.

Chiara Abbatantuono, Federica Alfeo, Livio Clemente, Giulio Lancioni, Maria Fara De Caro, Paolo Livrea, Paolo Taurisano

Open access · goldAbstract readReview
In one paragraph

Review in Brain sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Chiara AbbatantuonoDepartment of Translational Biomedicine and Neuroscience (DiBrain), University of Bari "Aldo Moro", 70121 Bari, Italy.
Federica AlfeoDepartment of Education, Communication and Psychology (For.Psi.Com), University of Bari "Aldo Moro", 70121 Bari, Italy.ORCID 0000-0002-0306-2122
Livio ClementeDepartment of Translational Biomedicine and Neuroscience (DiBrain), University of Bari "Aldo Moro", 70121 Bari, Italy.ORCID 0000-0001-5463-0460
Giulio LancioniDepartment of Translational Biomedicine and Neuroscience (DiBrain), University of Bari "Aldo Moro", 70121 Bari, Italy.
Maria Fara De CaroDepartment of Translational Biomedicine and Neuroscience (DiBrain), University of Bari "Aldo Moro", 70121 Bari, Italy.
Paolo LivreaVilla Anita, SP22, 70038 Terlizzi, Italy.
Paolo TaurisanoDepartment of Translational Biomedicine and Neuroscience (DiBrain), University of Bari "Aldo Moro", 70121 Bari, Italy.
University of Bari Aldo Moro · ITAstronomical Observatory of Capodimonte · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Screening for early symptoms of cognitive impairment enables timely interventions for patients and their families. Despite the advances in dementia diagnosis, the current nosography of neurocognitive disorders (NCDs) seems to overlook some clinical manifestations and predictors that could contribute to understanding the conversion from an asymptomatic stage to a very mild one, eventually leading to obvious disease. The present review examines different diagnostic approaches in view of neurophysiological and neuropsychological evidence of NCD progression, which may be subdivided into: (1) preclinical stage; (2) transitional stage; (3) prodromal or mild stage; (4) major NCD. The absence of univocal criteria and the adoption of ambiguous or narrow labels might complicate the diagnostic process. In particular, it should be noted that: (1) only neuropathological hallmarks characterize preclinical NCD; (2) transitional NCD must be assessed through proactive neuropsychological protocols; (3) prodromal/mild NCDs are based on cognitive functional indicators; (4) major NCD requires well-established tools to evaluate its severity stage; (5) insight should be accounted for by both patient and informants. Therefore, the examination of evolving epidemiological and clinical features occurring at each NCD stage may orient primary and secondary care, allowing for more targeted prevention, diagnosis, and/or treatment of both cognitive and functional impairment.

Indexed as

cognitive impairmentdiagnostic criterianeurocognitive disordersstadial progression

Identifiers

PMID37891810
PMCPMC10605551
OpenAlexW4387502253

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.